| Identification | Back Directory | [Name]
1-Piperazineacetamide, 2-(aminocarbonyl)-N-(4-amino-2,6-dichlorophenyl)-4-[5,5-bis(4-fluorophenyl)pentyl]-, (2S)- | [CAS]
138681-29-5 | [Synonyms]
1-Piperazineacetamide, 2-(aminocarbonyl)-N-(4-amino-2,6-dichlorophenyl)-4-[5,5-bis(4-fluorophenyl)pentyl]-, (2S)- | [Molecular Formula]
C30H33Cl2F2N5O2 | [MOL File]
138681-29-5.mol | [Molecular Weight]
604.52 |
| Chemical Properties | Back Directory | [Boiling point ]
755.9±60.0 °C(Predicted) | [density ]
1.338±0.06 g/cm3(Predicted) | [storage temp. ]
room temp | [solubility ]
DMSO: 2mg/mL, clear | [form ]
powder | [pka]
12.37±0.70(Predicted) | [color ]
white to beige | [Optical Rotation]
[α]/D -23 to -29°, c =0.5 in ethanol |
| Hazard Information | Back Directory | [Uses]
(S)-Draflazine ((-)-Draflazine) is the (S)-configuration of Draflazine (HY-106841). (S)-Draflazine is a potent blocker of nucleoside transport[1]. | [Biological Activity]
Draflazine (R88021; (-)-R75231)is a potent nucleoside transporter ENT1 (SLC29A1) inhibitor with 370-fold selectivity over ENT2 (SLC29A2). R88021 exhibits 30- and 40-times higher affinity as (+)-R75231 (R88016) using calf lung membrane preparation (by [3H]R75231 & [3H]NBI displacement) and intact human erythrocytes (by [3H]NBMPR displacement)respectively. Draflazine is 20-times more potent as R88016 in enhancing adenosine potency against ADP-induced aggregation in human whole blood (IC50 = 0.5 μM vs 10 μM with 1 μM respective inhibitor)Draflazine and R75231but not R88016show cardioprotective efficacy against catecholamines infusion in rabbits in vivo. | [References]
[1] M. A. Bruce, et al. Kinetic Resolution of Piperazine-2-Carboxamide by Leucine Aminopeptidase. An Application in the Synthesis of the Nucleoside Transport Blocker (-) Draflazine. An International Journal for Rapid Communication of Synthetic Organic Chemistry Volume 25, 1995 - Issue 17 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|